OPTI Factor. Nutrient Delivery System
Nutrient Delivery System

OPTI Factor and Mitochondrial Function

OPTI Factor contains NT Factor® which is the most powerful proprietary substance to combat aging and fatigue.



A study to investigate the effects of polyunsaturated phosphatidyl-choline (PPC)a on aging — in general, as well as the particular matter of age-associated hearing loss, was conducted. Regarding the latter, this report supports that the Membrane Hypothesis of Aging (MHA, also known as the Mitochondrial Clock Theory of Aging) provides a plausible explanation for age-related hearing loss. According to this hypothesis, Reactive Oxygen Metabolites (ROM) are responsible for progressive insults on mitochondria and other cellular structures. Over an extended time period, these insults accumulate leading to a reduction in the energy generating capacity of the mitochondria, cellular demise and resultant senescence.

Soy lecithin is a source from which PPC can be extracted. PPC molecules are indispensable for cellular differentiation, proliferation and regeneration. High-energy functional and structural elements of all biological membranes, PPC plays a rate-limiting role in the activation of numerous membrane-located enzymes, including superoxide-dismutase and glutathione peroxidase, which are important antioxidants that protect cell membranes from damage by reactive active metabolites (ROM).

PPC are highly purified extracts of the semen of soybean, supplying the organism with nontoxic choline molecules with a high content in polyunsaturated fatty acids — in particular, linoleic acid. These PPC correspond to the body’s own PPC molecule. The physiologic functions of these phospholipids are related to the morphology of the biological membranes, the incorporation of these molecules into membranes and thus on the intact character of the structure of cell membranes.

There are several disease processes related to membrane damage for which clinical and pharmacological trials using PPC have been conducted. Effects of PPC on these various disorders have shown enhancement in cognitive performance of the aging brain, improvement of coronary, peripheral and cerebral blood flow, activation of liver metabolism and detoxification and promotion of gastrointestinal function by mucosal restoration. The current study was designed to investigate the effects of PPC on age-related hearing loss by evaluating its ability to preserve mitochondrial function, protect mitochondrial DNA from oxidative damage and preserve auditory sensitivity.

Harlan-Fischer 344 rats, 18-20 months of age, were used as the experimental subjects. The subjects were caged individually and maintained at 21 to 22° C in a 12:12 light-dark cycle.b A dose of 300mg/kg/day of NT Factorc was supplemented to each subject, by adding it to the oral diet. The animals were divided randomly into two groups (n = 7 for each group). Group-1 served as the control, and group-2 as the experimental group. At the onset of the study, Auditory Brainstem Responses were obtained to measure base-line hearing thresholds in all subjects. Age-associated changes in hearing sensitivities were then recorded at two-month intervals for six months. In order to assess age-related changes in mitochondrial function, mitochondrial membrane potentials were studied using flow cytometry. For this purpose, peripheral blood was obtained from each subject at the beginning and at the end of the protocol. At the conclusion, the subjects were euthanized (according to NIH protocol), and tissue samples were obtained from brain and cochlea (stria vascularis and auditory nerve) to study mitochondrial DNA deletion associated with aging. Ihis was achieved by amplifying the specific common aging mitochondrial deletion (4834-bp) by Polymerase Chain Reaction. DNA quantification was performed. The data obtained for each protocol was compared between the two groups and analyzed using ANOVA.

The effects of PPC on age-related hearing loss demonstrate a gradual age-associated decline in hearing sensitivities at all the frequencies tested (3, 6, 9, 12 and 18 kHz). These results are comparable to previous studies that have shown similar results under similar experimental conditions. There was a statistically significant preservation of hearing noted in the treated subjects at all frequencies, which was observed at four and six months of treatment. Overall, there was a continued decline in hearing in the control subjects and a statistically significant protective effect of PPC on the experimental subjects (p<.005).

Mitochondrial membrane poten-tials were recorded by flow cytometry as a measure of the uptake of Rhodamine 123 by mitochondria. This probe is specific for mitochondria as it is selectively taken up by the mitochondrial membrane. The intensity of this uptake corresponds directly to the mitochondrial activity and hence membrane potential. The data obtained from the two groups were averaged and statistical analysis was performed using ANOVA. The mean fluorescence intensity (MFI) in group-1 subjects measured 3190 and 2100 at the beginning and end of the study, respectively. Ths, approximately, 30% decline in membrane potential with time was statistically significant (p=O.OO3). Con-versely, the MFI in the experimental group remained essentially unchanged at 2990 from 3165 at the beginning of the study. This difference between the control and treated groups was statistically significant (p<O.O5), demonstrating the protective effect of PPC supplementation on mitochondrial membrane potential.

For the mtDNA deletion tests, mtDNA from brain, stria vascularis and auditory nerve were studied. In order to verify the presence of mtDNA, the ND-1 16S rRNA segment was identified, which is a highly preserved region of the mitochondrial genome. Specific primers for this segment and for the common aging deletion were synthesized in our laboratory. Equal quantities of DNA were used in all samples for standardization purposes. The PCR products identified the ND-1 16SrRNA region (a control to verify the presence of mitochondrial DNA) by a 6O1bp product in all samples and the common aging deletion (4834 bp deletion) by a 598 bp product. This aging deletion was identified in five of the seven control subjects and four of the experimental subjects. Quantitative deter-mination reveals a significantly lower ratio of this common aging deletion to the total mtDNA in the experimental subjects as compared to the control subjects. Based upon these findings we conclude that PPC has a protective effect on mitochondrial DNA damage and function.

Reactive Oxygen metabolites (ROM) are known to play important roles in many biochemical reactions that are critical in maintaining normal cell functions. Increasing evidence indicates that ROM are also important mediators of several forms of tissue damage, such as injuries associated with inflammatory responses, ischemic injuries to tissues, injuries resulting from the intracellular metabolism of chemicals and drugs, coronary artery disease, cerebrovascular accidents, age-related hearing loss and aging. The primary in vivo source of ROM appears to be the mitochondrial electron transport system during oxidative phosphorylation (during the process of energy generation). There are many other sources of ROM production including; prostaglandin biosynthesis, environmental contaminants, cigarette smoking, ionizing radiation and poor dietary regimens.

ROM generation occurs from periods of prolonged relative hypo perfusion, such as can be seen with arteriosclerosis and aging. It has been demonstrated that in the elderly population there is significantly decreased flow within the circulatory system in general,1-5 and the inner ear, in specific.6-9 Prolonged periods of reduced blood flow such as those accompanying aging lead to the formation of tissue damaging ROM. ROM have been implicated in injury to polyunsaturated fatty acids in cell membranes resulting in the process of auto-oxidation which is of great importance in the pathogenesis of cell membrane damage. They have also been shown to be mediators of mitochondrial DNA damage including the generation of mitochondrial DNA deletions (mtDNA del). MtDNA del have been associated with cellular and tissue dysfunction, age-related hearing loss,19 senescence and death. This sequence of events is the foundation of the membrane hypothesis of aging (MHA)8-10

Phospholipids are integral structural components of all biological membranes with PPC and phosphotidylethanolamine being the predominant types, quantitatively. They constitute the phospholipid bilayer structure of cellular membranes, which is responsible for membrane stability and cellular function. PPCs maintain and promote the activity of several membrane bound proteins and enzymes, including Na-K ATPase, adenylate cyclase and glutathione reductase. They are also known to be precursors of cytoprotective agents such as eicosanoids, prostaglandins and antioxidants.

These experiments suggest that NT Factor containing PPC may protect mitochondrial function by preserving the age-related decline in mitochondrial membrane potentials and hence their activity. Additionally, there was less mitochondrial DNA damage noted in the treated group. This may also explain the demonstrated effect of preservation of hearing loss associated with aging, by the ability of PPC to specifically up regulate cochlear mitochondrial function. There are many studies demonstrating the effects of mitochondrial metabolites on cognition and aging,11-18, 20-22 Additionally, recent work from our laboratory has shown that acetyl-Lcarnitine and a-lipoic acid delay the progression of age-related hearing loss by protecting cochlear mitochondrial DNA from oxidative damage.23 These results support the membrane hypothesis of aging and provide further evidence to support this theory as a possible explanation for age-related hearing loss. Thus, PPC may be one of many rational approaches to consider for the purpose of membrane preservation, enhanced mitochondrial function, reduction of age-associated mitochondrial DNA damage and slowing of some of the aging processes.

A. NT Factor™ is a registered trademark of Nutritional Therapeutics Inc. Smithtown, NY, USA. NT Factor is comprised of defatted rice bran, arginine, beet root fiber, black strap molasses, glycine, magnesium sulfate, polyunsaturated phosphatidylcholine (phospholipids), saponin (glycolipids), para-amino benzoate, leek, pantethine (bifidus growth factor), taurine, garlic, calcium borogluconate, omega-6 essential fatty acids, omega-3 essential fatty acids, artichoke, barley malt, potassium citrate, calcium sulfate, spirulina, bromelain, natural vitamin E, calcium ascorabte, alpha-lipoic acid, oligosaccharides, B-6, niacinamide, riboflavin, inositol, niacin, calcium pantothenate, thiamin, B-l2, bifidus, acidophilus, folic acid, chromium picolinate.

B. The experimental protocols were reviewed and approved by the Care for Experimental Animal Committee (CEAC) at the Henry Ford Health System. These protocols are in strict compliance with guidelines as established by the National Institute of Health.

C. NT Factor containing PPC procured from Nutritional Therapeutics, Smithtown, NY, USA.

1. Gates GA, Caspery DM, Clark Wet al. Presbyacusis. Otolaryngol Head & and Neck Surg 1986; 100: 266-271

2. Kimura RS, Schuknecht HF. The ultra structure of the human stria vascularis. Acta otolaryngologica. 1970; 69(6): 415-427

3. Harkins SW. Effects of age and interstimulus interval on the brain stem auditory evoked potential. Inter.J. Neuroscience. 1981; 15(1-2):107-118

4. Rosenhall U, Pederson K, Dotevall M. Effects of presbycusis and other types of hearing loss on auditory brain stem responses. Scand. Audiol. 1986; 15 (4): 179-185

5. Hoeffding V, Feldman ML. Changes with age in the morphology of the cochlear nerve in rats: light microscopy. J. comparitive neurology 1988; 276(4):537-546

6. Axelsson A. The cochlear blood vessels in guinea pigs of different ages. Acta Otolaryngol. (Stockh.) 1971; sept. 72 (3): 172-181

7. Seidman MD, Khan MJ, Dolan D, Quirk WS. Age-related differences in cochlear microcirculation and auditory brain stem response. Arch. Oto Head & Neck Surg 1996; 122: 122 1-1226

8. Wallace DC. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science. 1992 May 1; 2 56(5057): 628-32

9. Seidman MD, Bai U, Khan MJ et al. Association of Mitochondrial DNA deletions and cochlear pathology: A molecular biologic tool. Laryngoscope. 1996; 106: 777-783 10

10. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc. Natl. Acad, Sci. USA. 1994; 91:1077 1-10778

11. lmperato A, Ramacci TM, Angelucci L. Acetyl L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neuroscience letters. 1989: 107(1-3): 251-255

12. Ghirardi 0, Milano S, Ramacci MT, Angelucci L. Effects of acetyl L-carnitine chronic treatment on discrimination models in aged rats. Physiol. Behav. 1988;44(6): 769-773

13. Caprioli A, Ghirardi 0, Ramacci MT, Angelucci L. Age-dependent deficits in radial maze performance in the rat: effect of chronic treatment with acetyl Lcarnitine. Prog. in Neuropsychopharmacol. Biol. Psychiatr. 1990; 14(3): 3 59-369

14. Bast A and Haenen GRMM. Interlay between lipoic acid and glutathione in the protection against microsomal lipid peroxidation. Biochem. Biophys. Acta. 1988; 963: 558-561

15. Suzuki YJ, Aggarwal B, Packer L. Aipha-lipoic acid is a potent inhibitor of NFKb activation in human T cells. Biochem. Biophys. Res. Commun. 1992; 189:1709-17 15

16. Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Poweel R, Packer L. Dihydrolipoic acid: A universal antioxidant both in the membrane and in the aqueous phase. Biochem Pharmacol. 1992; 44: 163 7-1649

17. Devasagayam TP, Subramanian M, Pradhan DS, Sies H. Chemical Biological Interactions. 1993; 86: 79-92

18. Gadaleta MN, Petruzalla V, Daddabbo L, et al. Mitochondrial DNA transcription and translation in aged rat. Effect of acetyl-L-carnitine. Ann.N.Y. Acad. Sci. 1994; 717: 150-160

19. Bai U, Seidman MD, Hinojosa R, Quirk WS. Mitochondrial DNA deletions associated with aging and possibly presbyacusis: A Human archival temporal bone study. Am.J. Otology. 1997; 18(4): 1-5

20. Paradies G, Ruggiero FM, Petrosillo G, Gadaleta MN, Quaglieriello E. Carnitine-acylcarnitine translocase activity in cardiac mitochondria from aged rats: the effect of acetyl-L-carnitine. Mech. of aging and develop. 1995; 84(2):103-1 12

21. Aureli T, Miccheli A, Ricciolini R, Di Cocco M, et al. Aging brain: effect of acetyl L-carnitine treatment on rat brain energy and phospholipid metabolism. A study by 3 1P and 1H NMR spectroscopy. Brain Research. 1990; 526(1):108-1 12

22. Sebinova E, Khwaja S, Reznick AZ, Packer L. Thioctic acid protects against ischemia-reperfusion injury in the isolated perfused Langendorif heart. Free Rad. Res. Commun. 1994; 17: 49-58

23. Seidman MD, Khan MJ, Bai U, Shirwany N, Quirk WS. Biologic Activity of Mitochondrial Metabolites on Aging and Age-Related Hearing Loss. Am. J. Otol. 2000;21:161-167.
Michael D. Seidman, MD., FACS, is a member of the Department of Otolaryngology Head and Neck Surgery at Henry Ford Health System, West Bloomfield, Michigan, USA



Home | Our Science | Fatigue | Video Testimonials | FAQ | Contact Us | Tell a Friend | Return Policy | Buy Now
Terms of Use | Site Map | Main Ingredient | Breaking News on Aging | Important Links | Bookmark This Site

OPTI Factor™ is marketed by Markit Health, LLC
This site is operated by Markit Health, LLC
Copyright © Markit Health, LLC

1465 Woodbury Avenue # 314
Portsmouth, NH 03801

© 2010 Markit Health, LLC. All Rights Reserved These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a health-care professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any pharmaceutical product without first consulting your prescribing physician.